Yesterday, Oct. 13, 2015, 64 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $43.89 to $672,000,000.00.

Highlighted Stocks Traded by Insiders:

Calavo Growers (CVGW) - FREE Research Report

Edwards Harold S, who is Director at Calavo Growers, sold 1,500 shares at $45.44 on Oct. 13, 2015. Following this transaction, the Director owned 4,900 shares meaning that the stake was reduced by 23.44% with the 1,500-share transaction.

The shares most recently traded at $45.09, down $0.35, or 0.78% since the insider transaction. Historical insider transactions for Calavo Growers go as follows:

  • 4-Week # shares sold: 255,751
  • 12-Week # shares sold: 46,018
  • 24-Week # shares sold: 349,882

The average volume for Calavo Growers has been 175,400 shares per day over the past 30 days. Calavo Growers has a market cap of $822.9 million and is part of the consumer goods sector and food & beverage industry. Shares are down 3.17% year-to-date as of the close of trading on Tuesday.

Calavo Growers, Inc. markets, and distributes avocados, prepared avocados, and other perishable foods to food distributors, produce wholesalers, supermarkets, convenience stores, and restaurants worldwide. It operates in three segments: Fresh Products, Calavo Foods, and RFG. The stock currently has a dividend yield of 1.58%. The company has a P/E ratio of 38.8. Currently, there are 2 analysts who rate Calavo Growers a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVGW - FREE

TheStreet Quant Ratings

rates Calavo Growers as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Calavo Growers Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Omnicell (OMCL) - FREE Research Report

Petersmeyer Gary S, who is Director at Omnicell, sold 670 shares at $31.66 on Oct. 13, 2015. Following this transaction, the Director owned 15,557 shares meaning that the stake was reduced by 4.13% with the 670-share transaction.

The shares most recently traded at $31.08, down $0.58, or 1.87% since the insider transaction. Historical insider transactions for Omnicell go as follows:

  • 4-Week # shares sold: 670
  • 12-Week # shares sold: 18,411
  • 24-Week # shares sold: 44,726

The average volume for Omnicell has been 230,000 shares per day over the past 30 days. Omnicell has a market cap of $1.1 billion and is part of the technology sector and computer software & services industry. Shares are down 5.37% year-to-date as of the close of trading on Tuesday.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates in two segments, Automation and Analytics, and Medication Adherence. The company has a P/E ratio of 37.1. Currently, there are 4 analysts who rate Omnicell a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMCL - FREE

TheStreet Quant Ratings

rates Omnicell as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Omnicell Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 215,000 shares at $85.86 on Oct. 13, 2015. Following this transaction, the 10% Owner owned 128.9 million shares meaning that the stake was reduced by 0.17% with the 215,000-share transaction.

The shares most recently traded at $79.94, down $5.92, or 7.4% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 510,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 535,000
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 2.0 million

The average volume for Eli Lilly and has been 5.4 million shares per day over the past 30 days. Eli Lilly and has a market cap of $88.1 billion and is part of the health care sector and drugs industry. Shares are up 15.41% year-to-date as of the close of trading on Tuesday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 2.52%. The company has a P/E ratio of 41.2. Currently, there are 7 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings

rates Eli Lilly and as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Eli Lilly and Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.